BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
You finally got a doctor's appointment. Here's how to get the most out of it - 2How federal officials talk about health is shifting in troubling ways – and that change makes me worried for my autistic child
- 3Vote in favor of the subject that you see as generally captivating and intelligent!
- 4Figure out How to Function Successfully with Your Auto Collision Legal advisor for the Best Result
- 5Vote In favor of Your Favored Kind Of Organic product
- The Most Paramount Crossroads in Olympic History
- The Tradition of Stone: A Gander at Notable Structures Through the Ages
- The 12 biggest space stories of 2025 — according to you
- Soldiers seize power in Guinea-Bissau and detain the president
- Golden Globes 2026 full nominations list: 'One Battle After Another' and 'The White Lotus' lead in film and television categories
- Tanzania president remorseful over internet shutdown on election day
- Pope Leo XIV calls for urgent climate action and says God’s creation is 'crying out'
- Rediscovering Euphoria: Individual Accounts of Conquering Despondency
- 6 Hints to Upgrade Your Appeal, In addition to Your Outlook
